Medical Services

Open Clinical Trials

The Beaufort Memorial Keyserling Cancer Center (KCC) strives to provide its patients with the latest, most effective cancer treatment available.

One component of cancer care that benefits current and future patients is the tracking of treatment effectiveness. Since 2007, KCC has collected patient information designed to advance treatment as well as prevention.

Clinical Trials:

  • Protocol S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer. e^3 Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy.
  • SCUSF 1102 A Cluster Randomized Controlled Trial Comparing Interventions to Enhance Utilization of Genetics Services Among Breast Cancer Patients
  • Protocol E1Z11  A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
  • Protocol DCP 001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
  • EAY 131: NCI- MATCH- (National Cancer Institute- Molecular Analysis for Therapy Choice) A phase ll study for patients with solid tumors or lymphomas that have progressed after standard systemic (oral or intravenous) therapy. 
  • EAY 131- MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment 
  • EAY 131- MATCH Treatment Subprotocol B: Phase II Study of Afatinib in Patients with Tumors with HER2 Activating Mutations
  • EAY 131- MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification
  • EAY 131- MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
  • EAY 131- MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR ·     
  • EAY 131- MATCH Treatment Subprotocol F: Crizotinib in Patients with Tumors (Other Than Adenocarcinoma of Lung or ALCL) with ALK Translocations      
  • EAY 131- MATCH Treatment Subprotocol G: Phase II Study of Crizotinib in Patients with ROS1 Translocations (Other Than Patients with Non-Small Cell Lung Cancer)       
  • EAY 131- MATCH Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma and Thyroid Cancer)       
  • EAY 131- MATCH Treatment Subprotocol I: GDC-0032 (taselisib) in Patients with Tumors (other than breast cancer) with PIK3CA Mutation but without KRAS Mutation or PTEN Loss       
  • EAY 131- MATCH Treatment Subprotocol N: Phase II Study of PI3K Beta Specific Inhibitor, GSK2636771, in Patients with Tumors with PTEN Mutation or Deletion, with PTEN Expression on IHC 
  • EAY 131- MATCH Treatment Subprotocol P: Phase II Study of PI3K Beta Specific Inhibitor, GSK2636771, in Patients with Tumors with PTEN Loss by IHC       
  • EAY 131- MATCH Treatment Subprotocol Q: Ado-trastuzumab Emtansine in Patients with Tumors with HER2 Amplification (Except Breast and Gastric/Gastro-Esophageal Junction (GEJ) Adenocarcinomas) 
  • EAY 131- MATCH Treatment Subprotocol R: Phase II Study of Trametinib in Patients with BRAF Fusions, or with Non-V600E, Non- V600K BRAF Mutations      
  • EAY 131- MATCH Treatment Subprotocol S1: Phase II Study of Trametinib in Patients with Tumors with NF1 mutations
  • EAY 131- MATCH Treatment Subprotocol S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations     
  • EAY 131- MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations      
  • EAY 131- MATCH Treatment Subprotocol U: VS-6063 (defactinib) in Patients with Tumors with NF2 Loss
  • EAY 131- MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor) ·     
  • EAY 131- MATCH Treatment Subprotocol W: Phase II Study of AZD4547 in Patients with Tumors with Aberrations in the FGFR Pathway
  • EAY 131- MATCH Treatment Subprotocol X: Phase II Study of Dasatinib in Patients with Tumors with DDR2 Mutations
  • EAY 131- MATCH Treatment Subprotocol Y: AZD5363 in Patients with Tumors with AKT Mutations      
  • EAY 131- MATCH Treatment Subprotocol Z1A: Binimetinib in Patients with Tumors (Other Than Melanoma) with NRAS Mutations
  • EAY 131- MATCH Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplification and Rb Protein Expression by IHC ·     
  • EAY 131- MATCH Treatment Subprotocol Z1D: Nivolumab in Patients with Tumors with Mismatch Repair Deficiency (Excluding Colorectal Cancer)  
  • A011401: Breast Cancer WEight Loss Study (BWEL Study) Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
  • S1507: Testing the combination of trametinib and docetaxel in advanced non-small cell lung cancer “A Phase II Trial of Trametinib with Docetaxel in Patients with KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies”

Beaufort Memorial Keyserling Cancer Center is a Community Cancer Program accredited by the American College of Surgeons Commission on Cancer.  Accreditation of a cancer center is granted only to those facilities that have voluntarily committed to provide the best in cancer diagnosis and treatment and are able to comply with established Commission on Cancer standards.




Find a Provider